NEUWAY focuses on the preclinical and clinical development of innovative therapeutics for treatment of severe orphan brain diseases based on its proprietary CNS Drug Delivery Platform.
To overcome the blood barrier is still a significant challenge for the treatment of CNS diseases. NEUWAY aims to become a leader in CNS Drug Delivery for a broad range of active drug substances. To achieve this goal, NEUWAY uses its CNS Drug Delivery Technology to encapsulate compounds that do not cross the blood brain barrier to successfully treat severe orphan brain diseases with very high medical need. NEUWAY is open to partner its CNS Drug Delivery Technology with pharmaceutical or biotech companies in particular if large indications, like, e.g., Alzheimer’s disease and Multiple Sclerosis, are addressed.